198 related articles for article (PubMed ID: 32506695)
1. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study.
Samaan MA; Cunningham G; Tamilarasan AG; Beltran L; Pavlidis P; Ray S; Mawdsley J; Anderson SH; Sanderson JD; Arkir Z; Irving PM
Aliment Pharmacol Ther; 2020 Jul; 52(2):292-302. PubMed ID: 32506695
[TBL] [Abstract][Full Text] [Related]
2. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
Taxonera C; Fernández-Aceñero MJ; Olivares D; Calvo M; Casis B; Bermejo F; López Serrano P; Iborra M; Mesonero F; Boscá Watts M; Díaz Del Arco C; Vera I; Olivares S; Algaba A; Alba C
Aliment Pharmacol Ther; 2022 Aug; 56(4):614-624. PubMed ID: 35509152
[TBL] [Abstract][Full Text] [Related]
3. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.
Magro F; Lopes S; Silva M; Coelho R; Portela F; Branquinho D; Correia L; Fernandes S; Cravo M; Caldeira P; Sousa HT; Patita M; Lago P; Ramos J; Afonso J; Redondo I; Machado P; Cornillie F; Lopes J; Carneiro F;
J Crohns Colitis; 2019 Oct; 13(11):1387-1393. PubMed ID: 30989180
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
[TBL] [Abstract][Full Text] [Related]
5. A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.
Dreesen E; Kantasiripitak W; Detrez I; Stefanović S; Vermeire S; Ferrante M; Bouillon T; Drobne D; Gils A
Inflamm Bowel Dis; 2020 Mar; 26(4):570-580. PubMed ID: 31372650
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.
Fumery M; Nancey S; Filippi J; Altwegg R; Hébuterne X; Boshetti G; Barraud M; Meynier J; Paul S; Roblin X
Aliment Pharmacol Ther; 2023 Jun; 57(11):1290-1298. PubMed ID: 36849714
[TBL] [Abstract][Full Text] [Related]
7. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.
Detrez I; Dreesen E; Van Stappen T; de Vries A; Brouwers E; Van Assche G; Vermeire S; Ferrante M; Gils A
J Crohns Colitis; 2016 May; 10(5):575-81. PubMed ID: 26738756
[TBL] [Abstract][Full Text] [Related]
8. Identification of Target Golimumab Levels in Maintenance Therapy of Crohn's Disease and Ulcerative Colitis Associated With Mucosal Healing.
Boland K; Greener T; Kabakchiev B; Stempak J; Tessolini J; Li R; Soriano J; Croitoru K; Nguyen G; Steinhart AH; Weizman AV; Silverberg MS
Inflamm Bowel Dis; 2020 Apr; 26(5):766-773. PubMed ID: 31676891
[TBL] [Abstract][Full Text] [Related]
9. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.
Berends SE; Strik AS; Jansen JM; de Boer NK; van Egmond PS; Brandse JF; Mathôt RA; D'Haens GR; Löwenberg M
Scand J Gastroenterol; 2019 Jun; 54(6):700-706. PubMed ID: 31132014
[No Abstract] [Full Text] [Related]
11. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis.
Walsh A; Kormilitzin A; Hinds C; Sexton V; Brain O; Keshav S; Uhlig H; Geddes J; Goodwin G; Peters M; Collins G; Travis S
J Crohns Colitis; 2019 Mar; 13(4):424-430. PubMed ID: 30445625
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit.
Hyams JS; Chan D; Adedokun OJ; Padgett L; Turner D; Griffiths A; Veereman G; Heyman MB; Rosh JR; Wahbeh G; Strauss R
Inflamm Bowel Dis; 2017 Dec; 23(12):2227-2237. PubMed ID: 29140944
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
15. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
Molander P; af Björkesten CG; Mustonen H; Haapamäki J; Vauhkonen M; Kolho KL; Färkkilä M; Sipponen T
Inflamm Bowel Dis; 2012 Nov; 18(11):2011-7. PubMed ID: 22223566
[TBL] [Abstract][Full Text] [Related]
16. Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.
Philip G; Cornillie F; Adedokun JO; Melsheimer R; Rutgeerts P; Colombel JF; Marano C
J Crohns Colitis; 2019 Sep; 13(10):1257-1264. PubMed ID: 30847474
[TBL] [Abstract][Full Text] [Related]
17. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
Telesco SE; Brodmerkel C; Zhang H; Kim LL; Johanns J; Mazumder A; Li K; Baribaud F; Curran M; Strauss R; Paxson B; Plevy S; Davison T; Knight L; Dibben S; Schreiber S; Sandborn W; Rutgeerts P; Siegel CA; Reinisch W; Greenbaum LE
Gastroenterology; 2018 Oct; 155(4):1008-1011.e8. PubMed ID: 29981298
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Drug Monitoring of Golimumab for the Prediction of Long-Term Clinical Remission in Patients with Ulcerative Colitis.
Tawa H; Kakimoto K; Numa K; Kinoshita N; Kawasaki Y; Tatsumi Y; Koshiba R; Nakata S; Hirata Y; Ota K; Sakiyama N; Kojima Y; Koubayashi E; Nishikawa H; Takeuchi T; Inoue T; Fukunishi S; Miyazaki T; Nakamura S; Higuchi K
Digestion; 2022; 103(5):329-338. PubMed ID: 35697000
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
[TBL] [Abstract][Full Text] [Related]
20. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
